UBS Group’s Fidelity Disruptive Medicine ETF FMED Stock Holding History

UBS Group’s Portfolio FMED Stock Details FMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3K	Buy	432 +201	+87%	+$5.09K	﹤0.01%	8451
2026 Q1	$5.67K	Buy	231 +10	+5%	+$260	﹤0.01%	8754
2025 Q4	$5.98K	Sell	221 -540	-71%	-$14.5K	﹤0.01%	8602
2025 Q3	$19K	Buy	761 +177	+30%	+$4.28K	﹤0.01%	8185
2025 Q2	$14K	Buy	+584	New	+$13.6K	﹤0.01%	8675
2025 Q1	–	Sell	-210	Closed	-$5.18K	–	10384
2024 Q4	$5.18K	Sell	210 -431	-67%	-$11.1K	﹤0.01%	8688
2024 Q3	$16.9K	Buy	641 +618	+2,687%	+$15.6K	﹤0.01%	7468
2024 Q2	$553	Buy	+23	New	+$555	﹤0.01%	8871
2024 Q1	–	Sell	-596	Closed	-$14.4K	–	9537
2023 Q4	$14.4K	Buy	596 +478	+405%	+$10.4K	﹤0.01%	7281
2023 Q3	$2.61K	Buy	+118	New	+$2.83K	﹤0.01%	7675

Other funds holding FMED

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.31B AUM 20.77% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $984M AUM 34.19% 1-Year Est. Return

GEA

Glen Eagle Advisors Kingston, New Jersey $793M AUM 21.06% 1-Year Est. Return

GJIA

Glass Jacobson Investment Advisors Owings Mills, Maryland $321M AUM 20.69% 1-Year Est. Return

UBS Group's FMED Position: Q2 2026 in Review

UBS Group increased its Fidelity Disruptive Medicine ETF (FMED) stake by 87% in Q2 2026, buying an estimated $5.09K and bringing the position to 432 shares worth $12.3K. The position accounts for ﹤0.01% of the portfolio, ranked #8451.

UBS Group first reported a position in FMED in Q3 2023 and has held it in 10 quarters since. The position peaked at $19K in Q3 2025. 11 funds tracked by Wall St. Rank hold FMED as of Q2 2026.

UBS Group held 432 shares of Fidelity Disruptive Medicine ETF worth $12.3K as of Q2 2026.
UBS Group bought 201 Fidelity Disruptive Medicine ETF shares in Q2 2026, an estimated $5.09K.
Fidelity Disruptive Medicine ETF made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8451 holding.
UBS Group first reported a position in Fidelity Disruptive Medicine ETF in Q3 2023 and has held it in 10 quarters since.
UBS Group's Fidelity Disruptive Medicine ETF position peaked at $19K in Q3 2025.
11 funds tracked by Wall St. Rank held Fidelity Disruptive Medicine ETF as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.